Thalidomide thromboprophylaxis in multiple myeloma: A review of current evidence
- 23 April 2012
- journal article
- review article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 8 (4) , 319-324
Abstract
Currently multiple antithrombotic agents are used for thalidomide thromboprophylaxis in multiple myeloma patients. Agents used include low-dose aspirin, fixed low-dose and therapeutic warfarin and prophylactic low molecular weight heparin. To evaluate the evidence for the efficacy and safety of aspirin, warfarin and low molecular weight heparin thromboprophylaxis in multiple myeloma patients on thalidomide a literature search was conducted in May and June 2011. Databases searched included the Cochrane Database of Systemic Reviews and the Database of Abstracts of Reviews of Effects, Evidence Based Medicine Reviews and Ovid MEDLINE. The search was restricted to English language articles and limited to articles published from 2005 to 2011. Most studies consisted of small prospective cohort studies not originally designed to assess thromboprophylaxis as an outcome. A single comparative randomized trial, several retrospective review articles, two meta-analyses and two clinical practice guidelines were also identified. Current evidence fails to demonstrate a clear advantage of any particular thromboprophylaxis strategy. Results from the only prospective comparative randomized trial found no significant differences among aspirin, warfarin and low molecular weight heparin. More studies are required that consider not only efficacy and safety, but also costs, lifestyle burden and patient preference.Keywords
This publication has 21 references indexed in Scilit:
- Multiple Myeloma, Venous Thromboembolism, and Treatment-Related Risk of ThrombosisSeminars in Thrombosis and Hemostasis, 2011
- Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta‐analysisJournal of Thrombosis and Haemostasis, 2011
- Tailored thromboprophylaxis for patients with multiple myeloma treated by IMIDsLeukemia & Lymphoma, 2008
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myelomaLeukemia, 2007
- Thalidomide and thrombosisThrombosis and Haemostasis, 2007
- Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomideJournal of Thrombosis and Haemostasis, 2006
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialThe Lancet, 2006
- Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinationsThrombosis and Haemostasis, 2006
- The Role of Aspirin in the Prevention of Thrombotic Complications of Thalidomide and Anthracycline-Based Chemotherapy for Multiple MyelomaMayo Clinic Proceedings, 2005
- Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple MyelomaJournal of Clinical Oncology, 2003